A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancer
Conditions
- Gastric Cancer
- Chemotherapy
- Immunotherapy
Interventions
- DRUG: Sintilimab 200 mg, intravenously (IV) every 3 weeks(Q3W)
Sponsor
Jiuda Zhao
Collaborators